Project Grant R21AI196824
Award Date 9/2/26
Completion Date 8/31/28
Dollars Obligated $190K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $228,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop enzymatic pipelines for the in vitro synthesis of parasitic glycosylphosphatidylinositol (GPI) anchors and GPI-anchored proteins. Parasitic infections affect more than one billion people globally. GPI anchors and GPI-anchored proteins are essential to parasite cell surfaces and...
- The National Institute of Allergy and Infectious Diseases awarded $436,750 to the University of Georgia Research Foundation on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct cellular and molecular profiling of artemisinin-induced persister phenotypes in Plasmodium falciparum. The research addresses the emergence of artemisinin resistance in malaria parasites and focuses on understanding how the parasites enter a dormant ring stage when exposed...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $675,790 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct molecular analysis of transcription termination by RNA polymerase II in trypanosomatids. The research investigates epigenetic mechanisms of gene expression control in Trypanosoma brucei and Leishmania species, protozoan parasites that cause human African sleeping...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded Mercer University $230,463 on July 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel malaria vaccine antigen targeting multiple stages of the Plasmodium lifecycle. The research combines transmission-blocking and liver-stage vaccine approaches into a single fusion construct. The work evaluates transmission-blocking efficacy of the HSP90N' domain and MG1 peptide targeting...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $1,023,862 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to produce and distribute filarial research reagents through the Filariasis Research Reagent Resource Center (FR3). The award funds three specific aims over a five-year period ending August 31, 2031. Under Aim 1, the recipient will ensure continued provision of high-quality...
- The National Institute of Allergy and Infectious Diseases awarded Kennesaw State University $144,000 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct comparative mechanistic and structural analysis of apicomplexan phosphoethanolamine N-methyltransferases for broad-spectrum antiparasitic discovery. The project will investigate phosphoethanolamine N-methyltransferases (PMTs), essential enzymes required for phosphatidylcholine biosynthesis in...
- The National Institute of Allergy and Infectious Diseases awarded Whitehead Institute for Biomedical Research $899,850 on February 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how apicomplexan parasites recognize and invade host cells. The funded research examines the molecular mechanisms by which parasites such as Toxoplasma and Plasmodium trigger rhoptry discharge—the secretion of proteins from specialized organelles upon contact with host...
- The National Institute of Allergy and Infectious Diseases awarded the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. $223,728 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate Plasmodium falciparum gametocyte differentiation and adhesion mechanisms as part of Project Grant R21AI199783. The funded research addresses malaria transmission by examining the sexual stage parasites (gametocytes) responsible for...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $228,000 on September 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855, Assistance Listing Project Grant R21AI202296). The award funds research determining the relationship between Trypanosoma cruzi parasite genetics and pathogen burden in infected hosts. The project addresses gaps in understanding why approximately 30% of T. cruzi-infected humans...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation, Inc. $264,633 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to optimize antivirals against poxviruses. The funded work advances preclinical development of modified carbocyclic nucleoside analogs targeting monkeypox virus (MPXV) and vaccinia virus (VACV). The research team identified a lead compound demonstrating potency of 187 nanomolar...